Home Forums Main Forum Media & News Drug companies paying hundreds of NHS officials

Viewing 7 posts - 1 through 7 (of 7 total)
  • Author
    Posts
  • #12096
    Avatar photoLondonGirl
    • Guardian Angel
    • ★★★★★
    @londongirl

    Weeeeelllll, who woudda thought it :angry:

    hundreds of NHS officials responsible for assessing which drugs should be prescribed to patients continue to be on the payroll of large pharmaceutical companies, an investigation has found.
    More than 140 members of health service staff are receiving generous consultancy fees from the same drugs companies whose products they are responsible for considering on behalf of the NHS.
    Ministers announced an urgent investigation last night and promised to take action against any officials found to have acted improperly after revelations made by The Daily Telegraph. MPs criticised the “murky” practice for the potential conflict of interest.

    http://www.thetimes.co.uk/tto/health/news/article4692556.ece

    and it’s not just ‘officials’ either but yes, clinicians, some whose education has been funded by drug companies, charities and ‘health’ forums


    GT1a Dec14 F2/8.7 VL 900000-2.5M
    Jan16 Hepcivir-L MonkMed/Redemption
    Baseline: VL 913575 Alt 76 Platelets low
    Wk2 VL1157 Alt 23
    DET Wk 8 VL 32 Alt19 ‘In the slow lane’
    June16 Fibro 5.7 F0/1 LIF 1.5
    Wk 11 VL<12 Alt 13 Det/Unq
    Extending tx 12 wks Mylan Sofo/Dac MonkMed
    Wk 14 VL <12 Det/Unq
    Wk 16 VL UNDETECTED
    Wk 22 + 4 Wks Sunprevir FixHepC
    Wk 24 UNDETECTED Alt 13
    Wk 12 post tx SVR12 Wk 26 SVR24
    Thank-you Tim, Dr Debasis @ MonkMed & Dr Freeman @ Fix HepC

    #12100
    Avatar photoPrice
    • Guardian Angel
    • ★★★★★
    @price

    Many of the doctors who participated in Gilead’s Sofosbuvir clinical trials are either paid speakers for Gilead or are members of Gilead’s advisory board. What’s even worse, Dr John Mchutchison who did at least 20 of Gilead’s Sofosbuvir studies (see link below) is Senior Vice President, Liver Disease Therapeutics for Gilead and is in charge of “research and development efforts supporting the company’s programs in liver disease, including hepatitis C”.(see second link).

    That is a HUGE conflict of interest and totally unethical. I can’t believe that he was allowed to do that.

    http://www.ncbi.nlm.nih.gov/pubmed/?term=McHutchison%20JG%5BAuthor%5D&cauthor=true&cauthor_uid=23607594

    http://www.gilead.com/news/press-releases/2010/6/john-g-mchutchison-md-to-join-gilead-sciences-as-senior-vice–president-liver-disease-therapeutics

    #12101
    Avatar photodointime
    • Guardian Angel
    • ★★★★★
    @dointime

    Just what I needed to start my day feeling homicidal. But that won’t do anybody any good.
    What will do good is to bring this shit into the light of day. Thank heavens it is happening!
    dt

    #12102
    Avatar photoLondonGirl
    • Guardian Angel
    • ★★★★★
    @londongirl

    Yes, my previous consultant’s education was funded by all the big pharma. He who lied to me and offered no monitoring which ever route I took and quite clearly wanted me to wait using emotional blackmail among other tricks along with two wopping lies, one on paper.

    Drug companies do need the advise of medical experts, it’s ho far that ‘advise’ goes … and if it gets into ‘murky waters’.

    The good news is, they’ve been rumbled, let’s hope UK ‘civil socity’ actually DO something about it.

    To think that these peoples actions cause restrictions to patients accessing these meds while raking in the dosh is uttery contemptable the fact that they work for the NHS makes it doubly so.


    GT1a Dec14 F2/8.7 VL 900000-2.5M
    Jan16 Hepcivir-L MonkMed/Redemption
    Baseline: VL 913575 Alt 76 Platelets low
    Wk2 VL1157 Alt 23
    DET Wk 8 VL 32 Alt19 ‘In the slow lane’
    June16 Fibro 5.7 F0/1 LIF 1.5
    Wk 11 VL<12 Alt 13 Det/Unq
    Extending tx 12 wks Mylan Sofo/Dac MonkMed
    Wk 14 VL <12 Det/Unq
    Wk 16 VL UNDETECTED
    Wk 22 + 4 Wks Sunprevir FixHepC
    Wk 24 UNDETECTED Alt 13
    Wk 12 post tx SVR12 Wk 26 SVR24
    Thank-you Tim, Dr Debasis @ MonkMed & Dr Freeman @ Fix HepC

    #12103
    Avatar photoLondonGirl
    • Guardian Angel
    • ★★★★★
    @londongirl

    Yes, the Times, The Telegraph and the Daily Snail so far, but some good MPs are asking questions.

    Plus of course, good ol’ Twitter. Please help spread the word UK people, don’t let them slither away with it ….


    GT1a Dec14 F2/8.7 VL 900000-2.5M
    Jan16 Hepcivir-L MonkMed/Redemption
    Baseline: VL 913575 Alt 76 Platelets low
    Wk2 VL1157 Alt 23
    DET Wk 8 VL 32 Alt19 ‘In the slow lane’
    June16 Fibro 5.7 F0/1 LIF 1.5
    Wk 11 VL<12 Alt 13 Det/Unq
    Extending tx 12 wks Mylan Sofo/Dac MonkMed
    Wk 14 VL <12 Det/Unq
    Wk 16 VL UNDETECTED
    Wk 22 + 4 Wks Sunprevir FixHepC
    Wk 24 UNDETECTED Alt 13
    Wk 12 post tx SVR12 Wk 26 SVR24
    Thank-you Tim, Dr Debasis @ MonkMed & Dr Freeman @ Fix HepC

    #12199
    Avatar photoPrice
    • Guardian Angel
    • ★★★★★
    @price

    The big difference is in whether the funding helps patients or helps yourself.

    I’m not ashamed to admit that I used to be a speaker for two drug companies. Back then, the medical group I was working for allowed patients a dose of Ribavirin of 800mg daily for all genotypes, while the rest of the world was using 1000mg-1200mg. My being a speaker gave the patients under my care the extra amount they needed from free samples When they got anemic it gave them Procrit which until then we’d been unable to get for them.

    I got paid $500 for doing a 45 min lecture. I did lectures for support groups and donated the money to them. You should have seen, I was a very popular speaker ;)

    #12206
    avatar876.jpegGaj
    • Guardian Angel
    • ★★★★★
    @gaj

    Thank you Price,

    I’ve noted a couple of times previously that the total segregation of pharma and medico is unlikely to be beneficial to the advancement of medicine or the welfare of patients in the real world. I would also suggest that it is not just about whether it helps the patient vs self but also any undue influence on decisions that can have long term consequences. It really comes down to how ‘cozy’ these arrangements become. This is exactly why we need, and have, ‘Conflict of Interest’ statements at the end of most academic papers, it doesn’t necessarily mean there a conflict but it allows everyone to see that there is a potential for it to occur. And allows others to ask questions to resolve any concerns.

    In my view, experts accepting monies to attend or speak at conferences, participate in study, conduct clinical trials, etc. that can’t/won’t be funded by governments, hospitals or the individual are within the bounds of acceptable behaviour providing they are declared, on subject and limited to reasonable costs. i.e. I don’t expect an Australian specialist flying to the AASLD conferences to stay in a caravan while he is there, but nor do I expect that he would be taken to Broadway shows unless he pays for the ticket himself.

    However, being a board member for a commercial corporation while having input to decisions by government/hospitals/etc. is not something that should be allowed. As such I also suspect the NHS officials commented on earlier should be disqualified from any decision processes that have anything at all to do with those from who they have received funding.


    G3a since ’78 – Dx ’12 – F4 (2xHCC)
    24wk Tx – PEG/Riba/Dac 2013 relapsed
    24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
    16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
    SVR7 – 22/06/17 UND
    SRV12 – 27/07/17 UND
    SVR24 – 26/10/17 UND
    :cheer: :cheer: :cheer:

Viewing 7 posts - 1 through 7 (of 7 total)
  • You must be logged in to reply to this topic.